Test ID VZPG Varicella-Zoster Antibody, IgG, Serum
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)
Secondary ID
34944Useful For
Determination of immune status of individuals to the varicella-zoster virus (VZV)
Documentation of previous infection with VZV in an individual without a previous record of immunization to VZV
Method Name
Multiplex Flow Immunoassay (MFI)
Reporting Name
Varicella-Zoster Ab, IgG, SSpecimen Type
SerumSpecimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Clinical Information
Varicella-zoster virus (VZV), a herpes virus, causes 2 distinct exanthematous (rash-associated) diseases: chickenpox (varicella) and herpes zoster (shingles). Chickenpox is a highly contagious, though typically benign, disease, usually contracted during childhood. Chickenpox is characterized by a dermal vesiculopustular rash that develops in successive crops approximately 10 to 21 days following exposure.(1) Although primary infection with VZV results in immunity and protection from subsequent infection, VZV remains latent within sensory dorsal root ganglia and upon reactivation, manifests as herpes zoster or shingles. During reactivation, the virus migrates along neural pathways to the skin, producing a unilateral rash, usually limited to a single dermatome. Shingles is an extremely painful condition typically occurring in older nonimmune adults or those with waning immunity to VZV and in patients with impaired cellular immunity.(2)
Individuals at risk for severe complications following primary VZV infection include pregnant women, in whom the virus may spread through the placenta to the fetus, causing congenital disease in the infant. Additionally, immunosuppressed patients are at risk for developing severe VZV-related complications, which include cutaneous disseminated disease and visceral organ involvement.(2,3)
Serologic screening for IgG-class antibodies to VZV aids in identifying nonimmune individuals.
Reference Values
Vaccinated: Positive (≥1.1 AI)
Unvaccinated: Negative (≤0.8 AI)
Reference values apply to all ages.
Cautions
IgG-class antibodies to varicella-zoster virus may be present in serum specimens from individuals who have received blood products within the past several months but have not been immunized or experienced past infection with this virus.
Serum specimens drawn early during acute phase of infection may be negative for IgG-class antibodies to this virus.
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 3 daysPerforming Laboratory

Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86787